GlobeStar Therapeutics Corp: 10-K filed 2020-12-03

Name: GlobeStar Therapeutics Corp: 10-K filed 2020-12-03
Creator: GlobeStar Therapeutics Corp

What GlobeStar Therapeutics Corp reported in its annual report filed 2020-12-03 (fiscal FY 2020): 27 published measures, 54 facts as tagged in accession 0001161697-20-000517.

This filing

Form: 10-K (annual report)
Filed: 2020-12-03
Fiscal period: fiscal FY 2020
Accession: 0001161697-20-000517 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-09-30	89,912	USD
At 2019-09-30	142,183	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2020-09-30	749,134	USD
At 2019-09-30	827,618	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2020-09-30	-659,222	USD
At 2019-09-30	-685,435	USD
At 2018-09-30	-870,731	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2020-09-30	81,442	USD
At 2019-09-30	100,459	USD
At 2018-09-30	91,597	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-541,731	USD	366
2018-10-01 to 2019-09-30	-675,072	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-239,735	USD	366
2018-10-01 to 2019-09-30	-260,138	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	1,782	USD	366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	77	USD	366
2018-10-01 to 2019-09-30	425	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	222,500	USD	366
2018-10-01 to 2019-09-30	269,000	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-1,782	USD	366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-09-30	-7,215,338	USD
At 2019-09-30	-6,673,607	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2020-09-30	1,275	USD
At 2019-09-30	822	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	35,500	USD	366
2018-10-01 to 2019-09-30	68,250	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-303,671	USD	366
2018-10-01 to 2019-09-30	-315,870	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-09-30	88,637	USD
At 2019-09-30	141,361	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	238,060	USD	366
2018-10-01 to 2019-09-30	360,363	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-09-30	749,134	USD
At 2019-09-30	827,618	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2020-09-30	2,412	USD
At 2019-09-30	40,115	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-37,605	USD	366
2018-10-01 to 2019-09-30	271	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-09-30	436,218,342	shares
At 2019-09-30	170,467,283	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-09-30	6,118,002	USD
At 2019-09-30	1,225,272	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2020-09-30	1,919	USD
At 2019-09-30	1,496	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-541,731	USD	366
2018-10-01 to 2019-09-30	-676,043	USD	365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-541,731	USD	366
2018-10-01 to 2019-09-30	-2,275,072	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	266,066	USD	366
2018-10-01 to 2019-09-30	316,141	USD	365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	1,329	USD	366
2018-10-01 to 2019-09-30	472	USD	365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2019-10-01 to 2020-09-30	-36	USD	366
2018-10-01 to 2019-09-30	36,300	USD	365

Inspect the source

Entity: GlobeStar Therapeutics Corp / CIK 0001502152
Captured: 2026-09-21T17:19:31.788Z
SEC response SHA-256: 6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))